What is Nabota and how does it compare to Botox?

Nabota is a botulinum toxin type A manufactured by South Korean company Daewoong Pharma, competing directly with Botox and other established toxins. It has achieved regulatory approval in South Korea, parts of Asia, and select European markets, but does not yet have FDA approval in the United States. Like other Type A toxins, it works identically for wrinkle reduction and muscle relaxation, with differences primarily in pricing, distribution, and regional availability.

Is Nabota available in the United States?

Nabota does not currently have FDA approval and is not available for clinical use in the U.S. market. It is approved in South Korea, parts of Asia, and has limited availability in select European countries. U.S. practitioners should continue to monitor regulatory developments, as Nabota's success in adjacent markets suggests potential for future American market entry.

How much has Nabota sold globally?

Nabota has exceeded 1 trillion won (approximately $750 million USD) in cumulative sales, with the majority driven by strong domestic performance in South Korea. This milestone demonstrates significant market traction and signals accelerating international uptake, particularly in Asia and Europe.

Could Nabota affect Botox pricing and market competition?

Yes—Nabota's global momentum and success as a non-Allergan Type A toxin could intensify competitive pressure on Allergan's pricing and rebate structures, particularly if Nabota gains traction in Europe or secures U.S. FDA approval. This competitive dynamic may benefit practices through improved pricing leverage and more options for toxin sourcing.

What markets currently offer Nabota?

Nabota is currently approved and available in South Korea (its primary market), select Asian countries, and limited European markets. The company is actively pursuing broader international expansion, but availability remains geographically restricted outside these regions.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Injectables

Daewoong Pharma's Nabota Surpasses 1 Trillion Won in Sales — South Korean Toxin Accelerates Global Expansion

Nabota's domestic milestone signals momentum in international markets as a third-party botulinum toxin alternative.

By Evan at Inside MedSpa · Jul 19, 2026

1-YEAR MOVE

ABBV ▲11.6%

1-year price move by ticker
Ticker	Company	1-year change
ABBV	AbbVie (Allergan Aesthetics)	+11.6%

Daewoong Pharma has announced that Nabota (botulinum toxin type A) has exceeded 1 trillion won (approximately $750 million USD) in cumulative sales, driven primarily by strong domestic performance in South Korea and accelerating international uptake. Nabota represents a third-party botulinum toxin competing against the established Type A franchise (Allergan, Galderma, Revance) in markets where regulatory pathways and reimbursement allow.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/daewoong-pharma-nabota-exceeds-1-trillion-won-sales/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

Daewoong Pharma's Nabota Surpasses 1 Trillion Won in Sales — South Korean Toxin Accelerates Global Expansion

Share

Discussion

Leave a comment

By the time it's news, it's too late.